Life Sciences

  • March 18, 2026

    NC Judge Moves Ex-Exec's Wage Fight With Cancer Co. To Va.

    A North Carolina federal judge agreed to transfer a former C-suite executive's unpaid wages case against a Canadian cancer testing and treatment company to Virginia, where its U.S. headquarters are, finding the Old Dominion is the better venue.

  • March 18, 2026

    Food Cos. Get Another Shot At David Protein Antitrust Case

    A New York federal court is letting low-calorie food producers take another shot at their antitrust claims accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after purchasing the ingredient's only supplier.

  • March 18, 2026

    DLA Piper Lands Shook Hardy Products Liability Pro In Miami

    A longtime Shook Hardy & Bacon LLP trial lawyer specializing in high-stakes product liability and complex litigation has joined DLA Piper in Miami, the firm announced Wednesday.

  • March 18, 2026

    Axion Cleared Of False Advertising Before Agilent Patent Trial

    Ahead of a patent infringement trial set to begin next week, a Delaware federal judge has addressed false advertising claims against biotechnology firm Axion and ruled there was no genuine dispute that a set of Axion advertisements deceived customers.

  • March 18, 2026

    Biotech Investor Blames Pierce Atwood For Messy Asset Sale

    A Ukrainian billionaire who was recently ordered to pay other investors in a failed genetic testing company more than $1.8 million in damages is blaming the Pierce Atwood LLP lawyers who advised him on what a court later found to be a "fundamentally unfair" forced asset sale.

  • March 18, 2026

    Latham Hires Desmarais IP Partner In DC

    Latham & Wakins LLP has hired a Desmarais LLP partner in D.C., who helped represent GlaxoSmithKline Biologicals in an ongoing infringement suit against Moderna Inc., the firm announced Tuesday.

  • March 17, 2026

    Pot Co. Escapes Potency Suit, Judge Warns Plaintiff Firm

    MariMed and other cannabis companies beat claims they intentionally mislabeled their products to sidestep Illinois THC potency limits, with a federal judge highlighting the string of consumer-led suit losses and warning counsel to "heed the strong and universal concerns about the plausibility of their legal theories."

  • March 17, 2026

    NeoGenomics Beats Investor Suit Over Growth Driver Claims

    Cancer diagnostics company NeoGenomics Inc. no longer faces a proposed investor class action alleging it mischaracterized its growth drivers, including by failing to disclose that a rainmaking unit potentially ran afoul of anti-kickback laws, after a Manhattan federal judge held the suit failed to show the company had intentionally misled the markets. 

  • March 17, 2026

    9th Circ. Backs Rare FCA Theory In Huge Drug Prices Program

    In a novel and potentially far-reaching decision, the Ninth Circuit on Tuesday revived a major hospital chain's False Claims Act suit accusing large pharmaceutical companies of massive overcharges in a prominent drug discount program where pricing disputes are common.

  • March 17, 2026

    Bard And AngioDynamics Resolve 11-Year Patent Dispute

    A Delaware federal judge on Tuesday closed the book on a vascular port patent dispute between C.R. Bard and AngioDynamics that had been pending for over 11 years, citing a settlement after the Federal Circuit invalidated Bard patents that a jury said AngioDynamics infringed.

  • March 17, 2026

    Dr. Oz Claims Florida Also Has Healthcare Fraud Problem

    Dr. Mehmet Oz, the administrator for the Centers for Medicare & Medicaid Services, announced Tuesday that he is taking his efforts to combat healthcare-related fraud to Florida, where he says millions of dollars have been wasted on schemes involving durable medical equipment.

  • March 17, 2026

    Geico Keeps RICO, Fraud Claims In NY No-Fault Billing Suit

    Two New York companies must face the majority of claims in Geico's suit alleging they exploited the state's no-fault insurance laws by fraudulently billing Geico more than $2.7 million for unnecessary durable medical equipment, a federal judge ruled Tuesday.

  • March 17, 2026

    Bipartisan Bill To Waive $100K H-1B Fee Gets AMA Backing

    Medical organizations and a bipartisan group of lawmakers are backing federal legislation introduced Tuesday that would exempt physicians and other healthcare workers from the Trump administration's $100,000 fee on H-1B visas.

  • March 17, 2026

    Edwards Beats Heart Valve IP Suit Just Before Trial

    A Delaware federal judge has ruled in favor of Edwards Lifesciences Corp. in a patent infringement suit brought against it by rival Aortic Innovations LLC, finding that the term "frame" as it appears in the patent claims lacks written description.

  • March 17, 2026

    Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033

    Specialty drugmaker Fennec Pharmaceuticals has jointly announced with Indian multinational pharmaceutical company Cipla Ltd. that they had reached an agreement to settle patent infringement litigation in exchange for Cipla delaying the manufacture of a generic pediatric cancer drug until 2033.

  • March 17, 2026

    Alcon Drops $430M Lensar Deal Under Pressure From FTC

    Swiss eye care company Alcon Inc. has abandoned its planned purchase of a Florida-based maker of laser treatments for cataracts, Lensar Inc., after the Federal Trade Commission threatened to block the $430 million deal.

  • March 17, 2026

    WTO Must Extend Digital Trade Protections, Lawmakers Told

    The World Trade Organization's moratorium on digital trade measures must be extended and its scope strengthened in support of U.S. business interests, experts testifying before the U.S. House's trade panel told lawmakers Tuesday.

  • March 17, 2026

    Drug Developer GNQ To Go Public Via $500M SPAC Deal

    Techbio company GNQ Insilico has announced plans to go public by merging with special-purpose acquisition company IB Acquisition Corp. in a deal that values it at $500 million and was built by four law firms.

  • March 17, 2026

    McGuireWoods Adds Former CDC Scientist From McDermott

    McGuireWoods LLP said Tuesday that it has hired a former Centers for Disease Control and Prevention scientist from McDermott Will & Schulte LLP, touting his background as a microbiologist and his history advising healthcare clients.

  • March 17, 2026

    Fenwick Healthcare Regulatory Atty Rejoins Latham In LA

    Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.

  • March 16, 2026

    1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze

    The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.

  • March 16, 2026

    Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal

    A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.

  • March 16, 2026

    Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit

    Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.

  • March 16, 2026

    J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M

    A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.

  • March 16, 2026

    Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss

    Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.

Expert Analysis

  • E-Discovery Quarterly: Recent Rulings On Dynamic Databases

    Author Photo

    Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.

  • How Litigating Antitrust Fix Helped GTCR Prevail In Court

    Author Photo

    An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.

  • Series

    Building With Lego Makes Me A Better Lawyer

    Author Photo

    Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.

  • The Rise Of Trade Secret Specificity As A Jury Question

    Author Photo

    Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.

  • Series

    Law School's Missed Lessons: Networking 101

    Author Photo

    Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.

  • Defeating Estoppel-Based Claims In Legal Malpractice Actions

    Author Photo

    State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.

  • Trade Secret Rulings Reveal The Cost Of Poor Preparation

    Author Photo

    Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Growth, Harmonization In Focus As Hague System Turns 100

    Author Photo

    One hundred years after its establishment, the Hague System has grown into an important pillar of international design protection, offering a promising path toward even greater harmonization in design law as its geographic reach continues to expand, say attorneys at Sterne Kessler.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.